ArticleActive
Response to Comments: MolDX: Envisia, Veracyte, Idiopathic Pulmonary Fibrosis Diagnostic Test
A56366
Effective: April 4, 2019
Updated: December 31, 2025
Policy Summary
This document is a procedural notice (Response to Comments) regarding the MolDX Envisia (Veracyte) diagnostic test for idiopathic pulmonary fibrosis and records the comment period, notice period, and final LCD date. The provided text contains no clinical coverage criteria, indications, limitations, documentation requirements, or frequency limits.